Equities
Health CarePharmaceuticals & Biotechnology
  • Price (USD)70.88
  • Today's Change-0.85 / -1.18%
  • Shares traded9.78m
  • 1 Year change9.13%
  • Beta0.6170
Data delayed at least 15 minutes, as of Aug 04 2020 21:00 BST.
More ▼

Profile data is unavailable for this security.

About the company

Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company's portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions. Its products for HIV/AIDS patients include Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Truvada, Emtriva, Tybost and Vitekta. Its products for patients with liver diseases include Vemlidy, Epclusa, Harvoni, Sovaldi, Viread and Hepsera. It offers Zydelig to patients with hematology/oncology diseases. Its products for patients with various cardiovascular diseases include Letairis, Ranexa and Lexiscan. Its products for various inflammation/respiratory diseases include Cayston and Tamiflu. It had operations in more than 30 countries, as of December 31, 2016.

  • Revenue in USD (TTM)22.17bn
  • Net income in USD-257.00m
  • Incorporated1987
  • Employees11.80k
  • Location
    Gilead Sciences Inc333 LAKESIDE DRFOSTER CITY 94404United StatesUSA
  • Phone+1 (650) 574-3000
  • Fax+1 (650) 578-9264
  • Websitehttps://www.gilead.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
GILD:NSQ since
announced
Transaction
value
Forty Seven IncDeal completed02 Mar 202002 Mar 2020Deal completed2.19%4.88bn
Data delayed at least 15 minutes, as of Aug 04 2020 21:00 BST.

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Regeneron Pharmaceuticals Inc7.98bn2.28bn66.06bn8.10k32.415.9726.488.2819.9019.9069.66108.150.55780.88973.05985,160.5015.9317.8018.2020.7489.7292.1628.5625.673.7219.180.05570.0017.1822.77-10.9744.305.23--
Vertex Pharmaceuticals Incorporated5.40bn2.08bn72.81bn3.00k35.339.6733.3013.487.917.9120.5928.910.62643.678.601,800,895.0024.135.4829.326.9987.7187.5038.519.033.60--0.06490.0036.5948.30119.39--8.06--
Zoetis Inc6.34bn1.61bn73.38bn10.60k45.9626.6536.0611.583.363.3613.235.800.56571.356.55598,018.9014.3811.6216.4313.7169.7066.8325.4118.901.9110.300.701322.907.475.528.4620.8020.6417.02
Gilead Sciences, Inc.22.17bn-257.00m89.98bn11.80k--4.9621.924.06-0.2426-0.242617.5114.470.37223.336.731,879,153.00-0.481818.07-0.57721.8878.5783.42-1.2939.312.3113.44--25.341.46-2.04-1.34-14.958.17--
Bristol-Myers Squibb Co31.01bn954.00m133.73bn30.00k73.052.6826.334.310.8090.80916.6522.060.37794.645.261,033,533.001.198.561.4411.2169.1672.593.1617.511.515.320.483172.4515.8910.49-30.8911.419.712.64
Data as of Aug 04 2020. Currency figures normalised to Gilead Sciences Inc's reporting currency: US Dollar USD

Institutional shareholders

38.78%Per cent of shares held by top holders
HolderShares% Held
The Vanguard Group, Inc.as of 31 Mar 2020100.85m8.04%
Capital Research & Management Co. (Global Investors)as of 31 Mar 202095.98m7.65%
BlackRock Fund Advisorsas of 31 Mar 202066.32m5.29%
SSgA Funds Management, Inc.as of 31 Mar 202056.81m4.53%
Capital Research & Management Co. (International Investors)as of 31 Mar 202056.37m4.49%
Capital Research & Management Co. (World Investors)as of 31 Mar 202046.33m3.69%
Geode Capital Management LLCas of 31 Mar 202019.88m1.59%
Northern Trust Investments, Inc.(Investment Management)as of 31 Mar 202015.55m1.24%
Dodge & Coxas of 31 Mar 202015.11m1.21%
Norges Bank Investment Managementas of 31 Dec 201913.23m1.06%
More ▼
Data from 31 Dec 2019 - 31 Mar 2020Source: FactSet Research Systems Inc.
The Financial and Risk business of Thomson Reuters is now Refinitiv
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.